Linkage between growth retardation and pituitary cell morphology in a dystrophin-deficient pig model of Duchenne muscular dystrophy.

[1]  A. Hoeflich,et al.  Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver , 2018, Molecular metabolism.

[2]  Andreas Blutke,et al.  Sampling Strategies and Processing of Biobank Tissue Samples from Porcine Biomedical Models. , 2018, Journal of visualized experiments : JoVE.

[3]  C. McDonald,et al.  Why short stature is beneficial in duchenne muscular dystrophy , 2013, Muscle & nerve.

[4]  F. Dacheux.  Ultrastructural immunocytochemical localization of prolactin and growth hormone in the porcine pituitary , 2004, Cell and Tissue Research.

[5]  B. Wong,et al.  Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure , 2012, Neuromuscular Disorders.

[6]  A. Nakamura,et al.  Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications , 2011, Journal of Biomedicine and Biotechnology.

[7]  M. Nishihara,et al.  Generation of muscular dystrophy model rats with a CRISPR/Cas system , 2014, Scientific Reports.

[8]  Nicolas Deconinck,et al.  Expression of full-length utrophin prevents muscular dystrophy in mdx mice , 1998, Nature Medicine.

[9]  F. Cornelio,et al.  Growth hormone evaluation in duchenne muscular dystrophy , 1988, The Italian Journal of Neurological Sciences.

[10]  M. Zatz,et al.  Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. , 1986, American journal of medical genetics.

[11]  W. Scherle,et al.  A simple method for volumetry of organs in quantitative stereology. , 1970, Mikroskopie.

[12]  P. Morcos,et al.  Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  V. Milošević,et al.  Morphofunctional parameters of rat somatotrophes after acute and repeated immobilization or restraint stress. , 2019, Acta histochemica.

[14]  A. Pestronk,et al.  Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy , 2016, Neurology.

[15]  R. Wanke,et al.  Practicable methods for histological section thickness measurement in quantitative stereological analyses , 2018, PloS one.

[16]  F. Dacheux.  Functional differentiation of the anterior pituitary cells in the fetal pig , 1984, Cell and Tissue Research.

[17]  L. Saccá,et al.  A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. , 2003, European heart journal.

[18]  A. Doering,et al.  Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  A. Ferlini,et al.  Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14‐year follow‐up , 2012, Muscle & nerve.

[20]  M. Grynpas,et al.  Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid‐Treated Mdx Mice, Model of Duchenne Muscular Dystrophy , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  Kenji Nakamura,et al.  Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. , 1997, Biochemical and biophysical research communications.

[22]  V. Howard,et al.  Unbiased Stereology: Three-Dimensional Measurement in Microscopy , 1998 .

[23]  F. Muntoni,et al.  A Duchenne Muscular Dystrophy Gene Hot Spot Mutation in Dystrophin-Deficient Cavalier King Charles Spaniels Is Amenable to Exon 51 Skipping , 2010, PloS one.

[24]  K. Bushby,et al.  Short stature and pubertal delay in Duchenne muscular dystrophy , 2015, Archives of Disease in Childhood.

[25]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[26]  R. Wanke,et al.  Missense Mutation of POU Domain Class 3 Transcription Factor 3 in Pou3f3L423P Mice Causes Reduced Nephron Number and Impaired Development of the Thick Ascending Limb of the Loop of Henle , 2016, PloS one.

[27]  I. Renner-Müller,et al.  Genetic dissection of IGF1-dependent and -independent effects of permanent GH excess on postnatal growth and organ pathology of mice , 2014, Molecular and Cellular Endocrinology.

[28]  P. Hüppi,et al.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. , 2012, The Journal of clinical investigation.

[29]  Qichun Huang,et al.  Effect of betaine on growth hormone pulsatile secretion and serum metabolites in finishing pigs. , 2007, Journal of animal physiology and animal nutrition.

[30]  R. Wanke,et al.  Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy , 2016, Scientific Reports.

[31]  E. Boltshauser,et al.  Short stature: a common feature in Duchenne muscular dystrophy , 1988, European Journal of Pediatrics.

[32]  R. Wanke,et al.  Tissue Sampling Guides for Porcine Biomedical Models , 2016, Toxicologic pathology.

[33]  J. Kopchick,et al.  Growth Hormone Resistance—Special Focus on Inflammatory Bowel Disease , 2017, International journal of molecular sciences.

[34]  Akinori Nakamura,et al.  Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs , 2009, Annals of neurology.

[35]  M. Zatz,et al.  Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy. , 1988, American journal of medical genetics.

[36]  R. Bartlett,et al.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. , 1992, Genomics.

[37]  K. Davies,et al.  The role of utrophin in the potential therapy of Duchenne muscular dystrophy , 2002, Neuromuscular Disorders.

[38]  John M. Shelton,et al.  Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy , 2018, Science.

[39]  E. Kardami,et al.  The pituitary-muscle axis in mdx dystrophic mice , 1994, Journal of the Neurological Sciences.

[40]  P. Shieh.  Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy , 2018, Neurotherapeutics.

[41]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[42]  D. C. Sterio.  The unbiased estimation of number and sizes of arbitrary particles using the disector , 1984, Journal of microscopy.

[43]  A. Kaindl,et al.  Growth and psychomotor development of patients with Duchenne muscular dystrophy. , 2014, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[44]  M. Elmlinger,et al.  Short stature in Duchenne muscular dystrophy: a study of 34 patients , 1999, Acta paediatrica.

[45]  S. Tschanz,et al.  Design-based stereology: Planning, volumetry and sampling are crucial steps for a successful study. , 2014, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[46]  H. Fuchs,et al.  Uromodulin Retention in Thick Ascending Limb of Henle's Loop Affects SCD1 in Neighboring Proximal Tubule: Renal Transcriptome Studies in Mouse Models of Uromodulin-Associated Kidney Disease , 2014, PloS one.

[47]  M. Zatz,et al.  Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength , 2008, Neuromuscular Disorders.

[48]  D. Wells.  Tracking progress: an update on animal models for Duchenne muscular dystrophy , 2018, Disease Models & Mechanisms.

[49]  Y. Takeshima,et al.  Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup , 2017, Neuromuscular Disorders.

[50]  H. Gundersen,et al.  The isector: a simple and direct method for generating isotropic, uniform random sections from small specimens , 1992 .

[51]  M. Malagón,et al.  Secretory and Morphological Heterogeneity of Porcine Somatotropes during Postnatal Development , 1997, Journal of neuroendocrinology.

[52]  M. Castro-Magana,,et al.  Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy. , 1984, Journal of medical genetics.

[53]  L. Lai,et al.  A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9 , 2018, Disease Models & Mechanisms.

[54]  L. Anderson,et al.  Immunocytochemical distribution of somatotrophs in porcine anterior pituitary , 2004, Histochemistry and Cell Biology.

[55]  B. Cooper,et al.  Canine X-linked muscular dystrophy: Morphologic lesions , 1990, Journal of the Neurological Sciences.

[56]  Rogely Waite Boyce,et al.  Design-based Stereology , 2010, Toxicologic pathology.

[57]  M. Dahlhoff,et al.  The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation. , 2018, Biochimica et biophysica acta. General subjects.

[58]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[59]  F. Nguyen,et al.  Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. , 2002, Journal of comparative pathology.

[60]  M. Ochs,et al.  Alterations of mouse lung tissue dimensions during processing for morphometry: a comparison of methods. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[61]  M. Zatz,et al.  Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. , 1986, American journal of medical genetics.

[62]  C. Campbell,et al.  Fatigue in young people with Duchenne muscular dystrophy , 2020, Developmental medicine and child neurology.

[63]  S. Hadjiyannakis,et al.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy , 2018, Pediatrics.

[64]  Andreas Blutke,et al.  Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies , 2016, Toxicologic pathology.

[65]  M. Zatz,et al.  Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine. , 1989, American journal of medical genetics.

[66]  R. Wanke,et al.  Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. , 2013, Human molecular genetics.

[67]  E. Wolf,et al.  Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. , 2009, American journal of physiology. Renal physiology.

[68]  J. Slightom,et al.  Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. , 1996, Human molecular genetics.

[69]  F. Muntoni,et al.  Duchenne muscular dystrophy presenting with failure to thrive. , 1995, Archives of disease in childhood.

[70]  J R Nyengaard,et al.  Tissue shrinkage and unbiased stereological estimation of particle number and size * , 2001, Journal of microscopy.

[71]  M. Zatz,et al.  Muscular dystrophy-related quantitative and chemical changes in adenohypophysis GH-cells in golden retrievers. , 2007, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[72]  R. Wanke,et al.  Growth hormone (GH)‐transgenic insulin‐like growth factor 1 (IGF1)‐deficient mice allow dissociation of excess GH and IGF1 effects on glomerular and tubular growth , 2016, Physiological reports.

[73]  A. Hoeflich,et al.  Insulin‐like growth factor binding protein 2 (IGFBP‐2) separates hypertrophic and hyperplastic effects of growth hormone (GH)/IGF‐I excess on adrenocortical cells in vivo , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[74]  R. Griffiths,et al.  The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. , 1988, Journal of neurology, neurosurgery, and psychiatry.